Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
D Ferguson, BN Finck - Nature Reviews Endocrinology, 2021 - nature.com
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …
[HTML][HTML] Current treatment paradigms and emerging therapies for NAFLD/NASH
S Raza, S Rajak, A Upadhyay, A Tewari… - Frontiers in bioscience …, 2021 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …
Shared and distinct mechanisms of fibrosis
JHW Distler, AH Györfi, M Ramanujam… - Nature Reviews …, 2019 - nature.com
Fibrosis is defined as an excessive deposition of connective tissue components and can
affect virtually every organ system, including the skin, lungs, liver and kidney. Fibrotic tissue …
affect virtually every organ system, including the skin, lungs, liver and kidney. Fibrotic tissue …
Targeting metabolic dysregulation for fibrosis therapy
Fibrosis is the abnormal deposition of extracellular matrix, which can lead to organ
dysfunction, morbidity, and death. The disease burden caused by fibrosis is substantial, and …
dysfunction, morbidity, and death. The disease burden caused by fibrosis is substantial, and …
[HTML][HTML] KASL clinical practice guidelines: management of nonalcoholic fatty liver disease
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
Type 2 diabetes mellitus (T2DM) associated non-alcoholic fatty liver disease (NAFLD) is the
fourth-leading cause of death. Hyperglycemia induces various complications, including …
fourth-leading cause of death. Hyperglycemia induces various complications, including …
Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications
K Cusi - Gastroenterology, 2012 - Elsevier
As obesity reaches epidemic proportions, nonalcoholic fatty liver disease (NAFLD) is
becoming a frequent cause of patient referral to gastroenterologists. There is a close link …
becoming a frequent cause of patient referral to gastroenterologists. There is a close link …
[HTML][HTML] Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
In many countries worldwide, the burden of hepatocellular carcinoma (HCC) associated with
non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is …
non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is …
Targeting TGF-β signaling for the treatment of fibrosis
Transforming growth factor-β (TGF-β) is widely recognized as a core pathway of fibrosis.
Inhibition of TGF-β signaling may thus offer potential for antifibrotic therapies. Long-term …
Inhibition of TGF-β signaling may thus offer potential for antifibrotic therapies. Long-term …
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic
steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global …
steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global …